1. Segraves JM, Frishman WH. Highly sensitive cardiac troponin assays: a comprehensive review of their clinical utility. Cardiol Rev. 2015;23(6):282-9.
2. Dadas A, Washington J, Marchi N, Janigro D. Improving the clinical management of traumatic brain injury through the pharmacokinetic modeling of peripheral blood biomarkers. Fluids Barriers CNS. 2016;13(1):21.
3. Bargerstock E, Puvenna V, Iffland P, Falcone T, Hossain M, Vetter S, et al. Is peripheral immunity regulated by blood-brain barrier permeability changes? PLoS One. 2014;9(7):e101477.
4. Pham N, Fazio V, Cucullo L, Teng Q, Biberthaler P, Bazarian JJ, et al. Extracranial Sources of S100B Do Not Affect Serum Levels. Plos One. 2010;5(9):e12691.
5. Preston E, Webster J, Small D. Characteristics of sustained blood-brain barrier opening and tissue injury in a model for focal trauma in the rat. J Neurotrauma. 2001;18(1):83-92.
6. Kanner AA, Marchi N, Fazio V, Mayberg MR, Koltz MT, Siomin V, et al. Serum S100beta: a noninvasive marker of blood-brain barrier function and brain lesions. Cancer. 2003;97(11):2806-13.
7. Marchi N, Rasmussen P, Kapural M, Fazio V, Kight K, Mayberg MR, et al. Peripheral markers of brain damage and blood-brain barrier dysfunction. Restor Neurol Neurosci. 2003;21(3-4):109-21.
8. Kanner AA, Marchi N, Fazio V, Mayberg MR, Koltz MT, Siomin V, et al. Serum S100beta: a noninvasive marker of blood-brain barrier function and brain lesions. Cancer. 2003;97(11):2806-13.
9. Marchi N, Cavaglia M, Bhudia S, Hallene K, Janigro D. Peripheral markers of blood-brain barrier damage. Clinica Chimica Acta. 2004;342((1-2)):1-12.
10. Falcone T, Fazio V, Lee C, Simon B, Franco K, Marchi N, et al. Serum S100B: a potential biomarker for suicidality in adolescents? PLoS One. 2010;5(6):e11089.
11. Papa L, Silvestri S, Brophy GM, Giordano P, Falk JL, Braga CF, et al. GFAP out-performs S100beta in detecting traumatic intracranial lesions on computed tomography in trauma patients with mild traumatic brain injury and those with extracranial lesions. J Neurotrauma. 2014;31(22):1815-22.
12. Bouzat P, Francony G, Declety P, Brun J, Kaddour A, Renversez JC, et al. Can serum protein S100 beta predict neurological deterioration after moderate or minor traumatic brain injury? Annales Francaises D Anesthesie et de Reanimation. 2009;28(2):135-9.
13. Hasselblatt M, Mooren FC, von Ahsen N, Keyvani K, Fromme A, Schwarze-Eicker K, et al. Serum S100beta increases in marathon runners reflect extracranial release rather than glial damage. Neurology. 2004;62(9):1634-6.
14. Korfias S, Stranjalis G, Papadimitriou A, Psachoulia C, Daskalakis G, Antsaklis A, et al. Serum S-100B protein as a biochemical marker of brain injury: a review of current concepts. Curr Med Chem. 2006;13(30):3719-31.
15. Savola O, Pyhtinen J, Leino TK, Siitonen S, Niemela O, Hillbom M. Effects of head and extracranial injuries on serum protein S100B levels in trauma patients. J Trauma. 2004;56(6):1229-34.
16. Thelin EP, Jeppsson E, Frostell A, Svensson M, Mondello S, Bellander BM, et al. Utility of neuron-specific enolase in traumatic brain injury; relations to S100B levels, outcome, and extracranial injury severity. Crit Care. 2016;20:285.
17. Anderson RE, Hansson LO, Nilsson O, Dijlai-Merzoug R, Settergren G. High serum S100B levels for trauma patients without head injuries. Neurosurgery. 2001;48(6):1255-8.
18. Posti JP, Hossain I, Takala RS, Liedes H, Newcombe V, Outtrim J, et al. Glial Fibrillary Acidic Protein and Ubiquitin C-Terminal Hydrolase-L1 Are Not Specific Biomarkers for Mild CT-Negative Traumatic Brain Injury. J Neurotrauma. 2017.
19. Zhang Y, Zhu J, Xu H, Yi Q, Yan L, Ye L, et al. Time-Dependent Internalization of S100B by Mesenchymal Stem Cells via the Pathways of Clathrin- and Lipid Raft-Mediated Endocytosis. Front Cell Dev Biol. 2021;9:674995.
20. Pham N, Fazio V, Cucullo L, Teng Q, Biberthaler P, Bazarian JJ, et al. Extracranial sources of S100B do not affect serum levels. PLoS One. 2010;5(9).
21. Steiner J, Schiltz K, Walter M, Wunderlich MT, Keilhoff G, Brisch R, et al. S100B serum levels are closely correlated with body mass index: an important caveat in neuropsychiatric research. Psychoneuroendocrinology. 2010;35(2):321-4.
22. Kawata K, Rubin LH, Takahagi M, Lee JH, Sim T, Szwanki V, et al. Subconcussive Impact-Dependent Increase in Plasma S100beta Levels in Collegiate Football Players. J Neurotrauma. 2017;34(14):2254-60.
23. Zonner SW, Ejima K, Bevilacqua ZW, Huibregtse ME, Charleston C, Fulgar C, et al. Association of Increased Serum S100B Levels With High School Football Subconcussive Head Impacts. Front Neurol. 2019;10:327.
24. Tagge CA, Fisher AM, Minaeva OV, Gaudreau-Balderrama A, Moncaster JA, Zhang XL, et al. Concussion, microvascular injury, and early tauopathy in young athletes after impact head injury and an impact concussion mouse model. Brain. 2018;141(2):422-58.
25. Schulte S, Podlog LW, Hamson-Utley JJ, Strathmann FG, Struder HK. A systematic review of the biomarker S100B: implications for sport-related concussion management. J Athl Train. 2014;49(6):830-50.
26. Michetti F, Bruschettini M, Frigiola A, Abella R, Giamberti A, Marchese N, et al. Saliva S100B in professional sportsmen: High levels at resting conditions and increased after vigorous physical activity. Clin Biochem. 2011;44(2-3):245-7.
27. Watson P, Shirreffs SM, Maughan RJ. Blood-brain barrier integrity may be threatened by exercise in a warm environment. Am J Physiol Regul Integr Comp Physiol. 2005;288(6):R1689-R94.
28. Watson P, Black KE, Clark SC, Maughan RJ. Exercise in the heat: effect of fluid ingestion on blood-brain barrier permeability. Med Sci Sports Exerc. 2006;38(12):2118-24.
29. Schulte S, Schiffer T, Sperlich B, Kleinoder H, Holmberg HC. Serum Concentrations of S100B are not Affected by Cycling to Exhaustion With or Without Vibration. J Hum Kinet. 2011;30:59-63.
30. Koh SX, Lee JK. S100B as a marker for brain damage and blood-brain barrier disruption following exercise. Sports Med. 2014;44(3):369-85.
31. Janigro D, Bailey DM, Lehmann S, Badaut J, O'Flynn R, Hirtz C, et al. Peripheral Blood and Salivary Biomarkers of Blood-Brain Barrier Permeability and Neuronal Damage: Clinical and Applied Concepts. Front Neurol. 2020;11:577312.
32. Bailey DMea. Hypoxemia promotes blood-brain barrier destabilization of the neurovascular unit during extreme apnea in humans. Journal of Cerebral Blood Flow & Metabolism. 2022;2022 in press.
33. Dadas A, Janigro D. The role and diagnostic significance of cellular barriers after concussive head trauma. Concussion. 2018;3(1):Cnc53.
34. Janigro D, Kawata K, Silverman E, Marchi N, Diaz-Arrastia R. Is Salivary S100B a Biomarker of Traumatic Brain Injury? A Pilot Study. Front Neurol. 2020;11:528.
35. Marchi N, Cavaglia M, Fazio V, Bhudia S, Hallene K, Janigro D. Peripheral markers of blood-brain barrier damage. Clin Chim Acta. 2004;342(1-2):1-12.
36. Marchi N, Rasmussen PA, Kapural M, Fazio V, Cavaglia M, Janigro D. Peripheral markers of brain damage and blood-brain barrier dysfunction. Restorative Neurology and Neuroscience. 2003;21(3-4):109-21.
37. Plog BA, Dashnaw ML, Hitomi E, Peng WG, Liao YH, Lou NH, et al. Biomarkers of Traumatic Injury Are Transported from Brain to Blood via the Glymphatic System. Journal of Neuroscience. 2015;35(2):518-26.
38. Gill KL, Gardner I, Li L, Jamei M. A Bottom-Up Whole-Body Physiologically Based Pharmacokinetic Model to Mechanistically Predict Tissue Distribution and the Rate of Subcutaneous Absorption of Therapeutic Proteins. AAPS J. 2016;18(1):156-70.
39. Peters SA. Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis. Clin Pharmacokinet. 2008;47(4):261-75.
40. Heizmann CW, Fritz G, Schafer BW. S100 proteins: Structure, functions and pathology. Frontiers in Bioscience. 2002;7:D1356-D68.
41. Sepp A, Meno-Tetang G, Weber A, Sanderson A, Schon O, Berges A. Computer-assembled cross-species/cross-modalities two-pore physiologically based pharmacokinetic model for biologics in mice and rats. J Pharmacokinet Pharmacodyn. 2019;46(4):339-59.
42. Shah DK, Betts AM. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn. 2012;39(1):67-86.
43. Morquette P, Verdier D, Kadala A, Fethiere J, Philippe AG, Robitaille R, et al. An astrocyte-dependent mechanism for neuronal rhythmogenesis. Nat Neurosci. 2015;18(6):844-54.
44. Iverson GL, Posti JP, Ohman J, Blennow K, Zetterberg H, Luoto TM. Reliability of serum S100B measurement following mild traumatic brain injury: a comparison of assay measurements from two laboratories. Brain Inj. 2020;34(9):1237-44.
45. Bouvier D, Duret T, Rouzaire P, Jabaudon M, Rouzaire M, Nourrisson C, et al. Preanalytical, analytical, gestational and pediatric aspects of the S100B immuno-assays. Clin Chem Lab Med. 2016;54(5):833-42.
46. Rahim MA, Rahim ZH, Ahmad WA, Hashim OH. Can Saliva Proteins Be Used to Predict the Onset of Acute Myocardial Infarction among High-Risk Patients? Int J Med Sci. 2015;12(4):329-35.
47. Jasim H, Olausson P, Hedenberg-Magnusson B, Ernberg M, Ghafouri B. The proteomic profile of whole and glandular saliva in healthy pain-free subjects. Sci Rep. 2016;6:39073.
48. Okonkwo DO, Puffer RC, Puccio AM, Yuh EL, Yue JK, Diaz-Arrastia R, et al. Point-of-Care Platform Blood Biomarker Testing of Glial Fibrillary Acidic Protein versus S100 Calcium-Binding Protein B for Prediction of Traumatic Brain Injuries: A Transforming Research and Clinical Knowledge in Traumatic Brain Injury Study. J Neurotrauma. 2020.
49. Dadas A, Washington J, Diaz-Arrastia R, Janigro D. Biomarkers in traumatic brain injury (TBI): a review. Neuropsychiatr Dis Treat. 2018;14:2989-3000.
50. Azizi S, Hier DB, Allen B, Obafemi-Ajayi T, Olbricht GR, Thimgan MS, et al. A Kinetic Model for Blood Biomarker Levels After Mild Traumatic Brain Injury. Front Neurol. 2021;12:668606.